245 related articles for article (PubMed ID: 15677428)
21. Suppressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action.
Horstmann S; Dose T; Lucae S; Kloiber S; Menke A; Hennings J; Spieler D; Uhr M; Holsboer F; Ising M
Psychoneuroendocrinology; 2009 Feb; 34(2):238-248. PubMed ID: 18926641
[TBL] [Abstract][Full Text] [Related]
22. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
[TBL] [Abstract][Full Text] [Related]
23. MAOA gene polymorphisms and response to mirtazapine in major depression.
Tzeng DS; Chien CC; Lung FW; Yang CY
Hum Psychopharmacol; 2009 Jun; 24(4):293-300. PubMed ID: 19382113
[TBL] [Abstract][Full Text] [Related]
24. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study.
Saiz-Ruiz J; Montes JM; Ibáñez A; Díaz M; Vicente F; Pelegrín C; Viñas R; Arias F; Carrasco JL; Ferrando L
Hum Psychopharmacol; 2005 Aug; 20(6):435-40. PubMed ID: 16106478
[TBL] [Abstract][Full Text] [Related]
25. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
[TBL] [Abstract][Full Text] [Related]
26. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity.
Schüle C; Romeo E; Uzunov DP; Eser D; di Michele F; Baghai TC; Pasini A; Schwarz M; Kempter H; Rupprecht R
Mol Psychiatry; 2006 Mar; 11(3):261-72. PubMed ID: 16344854
[TBL] [Abstract][Full Text] [Related]
27. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder.
Kang RH; Wong ML; Choi MJ; Paik JW; Lee MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1317-21. PubMed ID: 17618721
[TBL] [Abstract][Full Text] [Related]
28. Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study.
Varia I; Venkataraman S; Hellegers C; Gersing K; Doraiswamy PM
Psychopharmacol Bull; 2007; 40(1):47-56. PubMed ID: 17285095
[TBL] [Abstract][Full Text] [Related]
29. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression.
Kang RH; Chang HS; Wong ML; Choi MJ; Park JY; Lee HY; Jung IK; Joe SH; Kim L; Kim SH; Kim YK; Han CS; Ham BJ; Lee HJ; Ko YH; Lee MS; Lee MS
J Psychopharmacol; 2010 Dec; 24(12):1755-63. PubMed ID: 19493959
[TBL] [Abstract][Full Text] [Related]
30. Persistence of abnormal cortisol levels in elderly persons after recovery from major depression.
Beluche I; Chaudieu I; Norton J; Carrière I; Boulenger JP; Ritchie K; Ancelin ML
J Psychiatr Res; 2009 May; 43(8):777-83. PubMed ID: 19054531
[TBL] [Abstract][Full Text] [Related]
31. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects.
Schüle C; Baghai T; Laakmann G
Neuroendocrinology; 2004 Jan; 79(1):54-62. PubMed ID: 14755134
[TBL] [Abstract][Full Text] [Related]
32. A risk-benefit assessment of mirtazapine in the treatment of depression.
Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
[TBL] [Abstract][Full Text] [Related]
33. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice.
Grasmäder K; Verwohlt PL; Kühn KU; Frahnert C; Hiemke C; Dragicevic A; von Widdern O; Zobel A; Maier W; Rao ML
Pharmacopsychiatry; 2005 May; 38(3):113-7. PubMed ID: 15902580
[TBL] [Abstract][Full Text] [Related]
34. Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls.
Hennings JM; Ising M; Grautoff S; Himmerich H; Pollmächer T; Schaaf L
Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):98-100. PubMed ID: 19834872
[TBL] [Abstract][Full Text] [Related]
35. Mirtazapine-induced manic switch in adolescent unipolar depression.
Goyal N; Sinha VK
Aust N Z J Psychiatry; 2008 Dec; 42(12):1070-1. PubMed ID: 19031640
[No Abstract] [Full Text] [Related]
36. Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial.
Kang EH; Lee IS; Chung SK; Lee SY; Kim EJ; Hong JP; Oh KS; Woo JM; Kim S; Park JE; Yu BH
Psychiatry Res; 2009 Sep; 169(2):118-23. PubMed ID: 19695711
[TBL] [Abstract][Full Text] [Related]
37. Cognitive impairment in major depression: association with salivary cortisol.
Hinkelmann K; Moritz S; Botzenhardt J; Riedesel K; Wiedemann K; Kellner M; Otte C
Biol Psychiatry; 2009 Nov; 66(9):879-85. PubMed ID: 19709646
[TBL] [Abstract][Full Text] [Related]
38. Endocrinological effects of mirtazapine in healthy volunteers.
Schüle C; Baghai T; Bidlingmaier M; Strasburger C; Laakmann G
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1253-61. PubMed ID: 12502011
[TBL] [Abstract][Full Text] [Related]
39. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.
Gambi F; De Berardis D; Campanella D; Carano A; Sepede G; Salini G; Mezzano D; Cicconetti A; Penna L; Salerno RM; Ferro FM
J Psychopharmacol; 2005 Sep; 19(5):483-7. PubMed ID: 16166185
[TBL] [Abstract][Full Text] [Related]
40. Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety.
Wålinder J; Prochazka J; Odén A; Sjödin I; Dahl ML; Ahlner J; Bengtsson F
Hum Psychopharmacol; 2006 Apr; 21(3):151-8. PubMed ID: 16444795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
